Oragenics, Inc. OGEN
0.49
(0.01)
(2.00%)
as of 25 Sep
- Market cap
- $2.3M
- P/E
- 0.4×
Follow OGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.12 | 4.67 | 4.73 | 3.97 | |
Current Ratio |
3.01 | 5.73 | 5.64 | 4.42 | |
Net Debt/EBITDA |
1.49 | 2.71 | 3.36 | 3.65 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 1.00 | 1.24 | 0.97 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.49) | (0.51) | (1.31) | (1.91) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.49) | (0.51) | (1.31) | (1.91) | |
Cash per Share |
0.87 | 1.42 | 3.89 | 7.31 | |
Shareholders Equity per Share |
0.83 | 1.44 | 3.84 | 6.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.83 | 1.44 | 3.84 | 6.30 | |
Free Cash Flow |
(2.19) | (2.20) | (2.84) | (2.98) | |
Working Capital |
3.67 | 6.18 | 8.28 | 9.83 | |
Net Current Asset Value |
3.67 | 6.18 | 8.28 | 9.83 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Receivables |
— | — | 0.04 | — | |
Average Payables |
1.54 | 1.21 | 1.46 | 2.04 | |
Average Assets |
3.82 | 5.68 | 5.77 | 8.95 | |
Average Common Equity |
0.77 | 3.16 | 4.03 | 5.66 |
Columns are period end dates